Biotech Stock Roundup: Alnylam Slumps On Revusiran Update, TESARO Impresses At ESMO

Alnylam focused on developing novel therapeutics based on RNA interference (RNAi), saw its shares slump on its decision to discontinue the development of a late-stage pipeline candidate.